Suraksha Diagnostics unveils eastern India’s largest & first state-of-the art genomics lab

New Delhi: Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India has launched one of the largest and a state-of-the-art genomics labs in Eastern India with a grand inauguration event which was graced by Prof. Sukumar Mukherjee, a distinguished rheumatologist with more than 35 years of extensive experience in the field and a mentor at Suraksha Diagnostics.

West Bengal, is a leader in education and culture in the whole of the country and in the current times, there is a resurgence in medical education and services in the state. Keeping in line with this resurgence, Suraksha Diagnostics recognized the urgent need for accessible genomic diagnostics in West Bengal. Its genomics lab aligns with the future of preventive care by enabling early, accurate risk detection and better treatment planning.

The global genetic testing market is valued at USD 38.77 billion (2024) and is projected to reach USD 186.64 billion by the year 2035 (CAGR: 22.5%). In a landmark move, Suraksha Diagnostics has invested ₹22 crores in establishing its Genomics Lab. An additional ₹46 crore investment is planned over the next 24 months to establish one of Asia’s most advanced Genomics Laboratories. This initiative is a significant leap forward for West Bengal, Eastern & North-Eastern India, and India’s future in precision diagnostics.

This State-of-the-Art Genomics Lab is equipped with Cytogenetics, Microarray Technology, Sanger Sequencing, Multiple Next-Generation Sequencers (NGS). Together, these technologies enable the full spectrum of advanced genetic testing, offering predictive, preventive, and personalized care.

Suraksha’s Genomics Lab enables the detection of chromosomal abnormalities like Down syndrome, Edwards syndrome, and Patau syndrome, as well as sex chromosome aneuploidies and microdeletions. These insights help expecting parents make informed decisions, supported by expert genetic counseling.

Suraksha’s Genomics Lab also pioneers Onco-genomics with advanced hereditary cancer testing panels, enabling early detection of genetic predispositions to breast, ovarian, and colorectal cancers. The lab offers both germline and somatic mutation profiling, aiding in personalized cancer risk assessment and treatment planning. With targeted oncology panels powered by NGS, clinicians can now identify actionable mutations for precision therapies. This makes Suraksha one of the few centres in Eastern India delivering truly personalized oncology diagnostics.

The lab’s genomics testing process starts with Karyotyping, a method that allows doctors to visualize all 46 chromosomes and identify missing or extra segments. For more detailed analysis, Chromosomal Microarray scans for smaller genetic changes, while FISH technology focuses on specific genetic issues. Sanger Sequencing is used to read individual genes with precision, and Next-Generation Sequencing (NGS) scans millions of genetic data points, offering deeper insights into complex health conditions.

Speaking on the launch of the genomics lab, Dr Somnath Chatterjee, Chairman and Joint Managing Director, Suraksha Diagnostics, said: “A huge transformation is sweeping across medicine today. At the heart of this revolution lies Genomics -unlocking the secrets of the Human Genome, enabling early diagnosis, predictive analytics, and personalized treatments. From Fetal Medicine to Oncology and Rare Diseases, genomic science is rewriting the future of healthcare. Suraksha Diagnostics is proud to be at the forefront of this revolution.”

Ritu Mittal, CEO and Managing Director, Suraksha Diagnostics, also emphasized the lab’s role in making genomic diagnostics a critical part of healthcare decisionmaking in Eastern India and shared: “We provide end-to-end solution for prenatal genetics, offering comprehensive testing facilities. We aim to be a premium, aspirational choice for clinicians and families seeking the highest standards in fetal, reproductive, paediatric and onco-genetics without the need to send samples out of the region or compromise on quality.”